307 related articles for article (PubMed ID: 33637708)
1. The application of BH3 mimetics in myeloid leukemias.
Parry N; Wheadon H; Copland M
Cell Death Dis; 2021 Feb; 12(2):222. PubMed ID: 33637708
[TBL] [Abstract][Full Text] [Related]
2. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
3. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
5. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
8. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic development and current uses of BCL-2 inhibition.
Roberts AW
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
[TBL] [Abstract][Full Text] [Related]
11. Pathways and mechanisms of venetoclax resistance.
Bose P; Gandhi V; Konopleva M
Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
[TBL] [Abstract][Full Text] [Related]
12. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
13. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
14. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
16. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
18. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
Vandenberg CJ; Cory S
Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
[TBL] [Abstract][Full Text] [Related]
19. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
20. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Adams JM; Cory S
Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]